Aug 6 (Reuters) - Precision BioSciences Inc DTIL.O:
PRECISION BIOSCIENCES ANNOUNCES PHASE 1 SAFETY AND EFFICACY FOR COHORT 1, LOWEST DOSE LEVEL IN ELIMINATE-B, A FIRST-IN-HUMAN TRIAL OF PBGENE-HBV FOR CHRONIC HEPATITIS B
PRECISION BIOSCIENCES INC - COHORT 1 ESTABLISHED SAFE AND WELL-TOLERATED PROFILE
PRECISION BIOSCIENCES INC - EXTENDED CASH RUNWAY TO SECOND HALF OF 2027
PRECISION BIOSCIENCES INC - PBGENE-HBV SHOWED 47-69% HBSAG REDUCTION